Stock Financial Ratios, Dividends, Split History

PRMW / Primo Water Corp. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)548.40
Enterprise Value ($M)822.28
Book Value ($M)66.45
Book Value / Share2.13
Price / Book8.32
NCAV ($M)-281.65
NCAV / Share-9.02
Price / NCAV-1.96
Share Statistics
Preferred Stock Shares Outstanding 0
Common Shares Outstanding 30,857,302
Common Stock Shares Outstanding 30,084,000
Weighted Average Number Of Shares Outstanding Basic 33,258,000
Weighted Average Number Of Diluted Shares Outstanding 33,258,000
Scoring Models
Piotroski F-Score3.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.02
Return on Assets (ROA)-0.02
Return on Equity (ROE)-0.10
Balance Sheet (mrq) ($M)
Quick Ratio0.90
Current Ratio1.05
Income Statement (mra) ($M)
Sales Revenue Net286,074,000.00
Operating Income14.04
Net Income-6.36
Earnings Per Share Basic-0.19
Earnings Per Share Diluted-0.19
Cash Flow Statement (mra) ($M)
Cash From Operations17.57
Cash from Investing-20.52
Cash from Financing17.57
Identifiers and Descriptors
Central Index Key (CIK)1365101
Related CUSIPS

Split History

Stock splits are used by Primo Water Corp. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

10 Blue-Chip Consumer Stocks to Buy | InvestorPlace

2018-06-15 investorplace
That means when the economic numbers are on the rise, the U.S. consumer is also on the rise. The Federal Reserve just raised interest rates for the second time this year and it says it will likely raise it two more times in 2018. And instead of rocking the market, the market took it as a positive sign that the 10-year economic doldrums may be at an end. I’ll take it one step at a time. (19-0)

Tracking Charles Akre's Akre Capital Management Portfolio - Q1 2018 Update

2018-05-27 seekingalpha
The top three positions are American Tower, MasterCard, and Moody’s and they add up to ~38% of the entire portfolio. (180-3)

Primo Water Corp's (PRMW) CEO Matthew Sheehan on Q1 2018 Results - Earnings Call Transcript

2018-05-12 seekingalpha
Good day, ladies and gentlemen, and welcome to the Primo Water First Quarter 2018 Financial Results. [Operator Instructions]. As a reminder, this call may be recorded. I would now like to introduce your host for today's conference, Ms. Katie Turner, Investor Relations. You may begin. (3-0)

6 Most Undervalued Stocks In Chuck Akre's Portfolio

2018-04-19 valuewalk
Chuck Akre is an illustrious investor with a 29-year track record and is the founder, chairman and chief investment officer of Akre Capital Management. I take a closer look at Akre’s investment strategy and the firm’s most undervalued stock holdings below. (102-1)

CUSIP: 74165N105